The demographics of autoimmune hepatitis in human immunodeficiency virus-infected patients: a United States cross-sectional study.

Introduction: Autoimmune hepatitis (AIH) is a chronic inflammatory condition of the liver with increasing global prevalence. However, no epidemiological data exist for AIH in human immunodeficiency virus (HIV)-infected patients. Aim: To determine the demographics and comorbid conditions associated with AIH among HIV-infected individuals in the United States. Material and methods: The United States National Inpatient Sample database was used to identify HIV hospital encounters in 2012-2014. The encounters were then classified into 2 groups based on a concomitant primary diagnosis of AIH. Primary outcomes included the demographics and comorbid conditions of AIH among HIV-infected patients. Secondary outcomes assessed the independent predictors of AIH. Results: A total of 48,3310 patients with an HIV diagnosis were included. The estimated AIH prevalence was 52.8/100,000 HIV hospital encounters. The female gender was more likely to have AIH with an odds ratio (OR) of 1.82; 95% confidence interval (CI) 1.42-2.32, p < 0.0001. The age intervals of 35-50 and 51-65 years had higher odds of AIH 110 (43.1%) and 115 (45.1%) with OR = 1.30; 95% CI: 1.02-1.67, p = 0.03 and OR = 1.34; 95% CI: 1.05-1.71, p = 0.02, respectively. African American and Hispanic races were more commonly affected. Moreover, HIV-infected patients with AIH had a higher risk of having elevated transaminases, long-term steroid use, rheumatoid arthritis, and ulcerative colitis. Conclusions: This study illustrates that the estimated prevalence of AIH in HIV-infected patients in the United States is 52.8/100,000. AIH in HIV-positive individuals has a predilection for the female gender and African American and Hispanic races, and shows a higher correlation with rheumatoid arthritis and ulcerative colitis.

Novel COVID-19: A Comprehensive Review of Transmission, Manifestation, and Pathogenesis.

A global outbreak highlights the start of a new decade as a new strain of coronaviruses emerges. Coronavirus disease 2019 (COVID-19), also referred to as Wuhan-Hu-1-CoV - amongst many other names - emerged from the West District of Southern China Seafood Wholesale Market in late December 2019. With the emergence of the new decade, the causative agent of COVID-19 was identified: severe acute respiratory syndrome coronavirus 2 (SARS-CoV2). COVID-19 became declared a global pandemic by the World Health Organization (WHO). COVID-19, currently, is affecting 204 countries and territories and two international conveyances. Initial stages of COVID-19 present with symptoms that mimic the common cold and individuals may be asymptomatic carriers and thus, transmitting the virus to others. COVID-19, like other coronaviruses, presents with S glycoproteins on the membrane that plays an integral role in the virus binding with the angiotensin-converting enzyme 2 (ACE2) receptor. The ACE2 receptor is an intramembrane receptor on the type II pneumocytes, where the virus is able to replicate after getting endocytosed within the cytoplasm. As the viral load increases within the alveolar cell, the alveolar epithelial cell will burst, releasing the newly replicated viral RNA. Elderly individuals are at a greater risk of infection due to weakened immune systems and pre-existing medical conditions resulting in a compromised immune response, also increasing the susceptibility of infection. Infected individuals presenting with mild to moderate symptoms are recommended to self-isolate as the majority will recover without any intervention.

Vitamin C: A Preventative, Therapeutic Agent Against Helicobacter pylori.

The treatment of Helicobacter pylori (H. pylori) induced infections using antibiotic therapies is clinically well accepted; however, using a noninvasive approach with the implementation of therapeutic agents such as vitamin C is not well investigated. Vitamin C has certain characteristics, which allow for it to be considered as a potential treatment option for patients with H. pylori infections. Vitamin C's hostility and mechanism of action towards H. pylori infection in peptic ulcer disease can be classified into two categories: as a preventative agent and alternatively as a therapeutic agent. Preventatively vitamin C acts as a biological antioxidant as well as an immune boosting agent, while therapeutically it acts as an inhibitor of urease, a potential collagen synthesizing agent, and a stimulant in prostaglandin synthesis. As a result, the dosage of vitamin C should be highly regulated. Furthermore, numerous studies have shown that vitamin C supplementation if taken with antibiotics can increase the efficiency of the treatment leading to an increased possibility of eradication of H. pylori in infected individuals. This paper will investigate the recent studies that show different mechanisms through which vitamin C can be used as a preventative or a therapeutic agent for the treatment of H. pylori related infections.

Cardiovascular Pathologies Associated with Excessive Energy Drink Consumption: A Review.

Energy drink consumption has caused worldwide concern in the scientific community and the general public regarding the health effects of these products. Current studies offer data about consumption patterns in America and Europe, but more extensive research is needed to ascertain the potential effects of energy drink consumption, especially among young and healthy individuals. To examine the consequences and health risks of energy drink consumption, related studies were reviewed. Health issues, including elevated blood pressure, palpitations, insomnia, jitters, and nervousness, are primarily associated with high caffeine content. Although more studies examine the effects of highly carbonated and caffeinated products, research determining the health effects of energy drinks is also important. Currently, the evidence regarding the adverse health effects of energy drinks is growing. Unfortunately, the risks of high consumption of energy drinks have not been properly addressed. Thus, these adverse effects may pose a great public health dilemma in the years to come.

Gastroesophageal Reflux Disease: A Review of Symptomatic Management.

Considered as a chronic illness, gastroesophageal reflux disease (GERD) has manifested itself as a widespread condition throughout the adult population. As a growing epidemic, GERD has reached a staggering prevalence of 10% to 20% in the Western world, by affecting up to 30 million people in the United States alone. Sixty percent of individuals in an adult population will experience symptoms and the impact of GERD over a period of 12 months, whereas a remarkable 20% to 30% of individuals will have weekly symptoms. This rapid increase in the prevalence of the disease requires equally rapid management techniques. Although the disease itself has no cure, management of symptoms and certain pharmacological and surgical advancements have allowed for individuals affected by GERD to receive specific treatment options sufficient for them to live a healthy life. In this paper, such management options will be examined and discussed in reference to their effectiveness in treating the symptoms presented in GERD patients.